Drug intelligence / Profile preview

H6

Development stage: Preclinical
Modality: Small Molecules

Overview

H6 is a small-molecule inhibitor of the programmed cell death ligand-1 (PD-L1) immune checkpoint, identified through a sequential virtual screening protocol involving pharmacophore screening and molecular docking. It has demonstrated a stable binding mode at the PD-L1 dimer interface. In biological evaluations, H6 induced higher levels of cytokines (IL-2, IL-6, and INF-γ) in peripheral blood mononuclear cells (PBMCs) from hepatocellular carcinoma (HCC) patients compared to BMS-202, suggesting its potential as a lead compound for the development of novel anti-hepatocellular carcinoma agents.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on H6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H6.

Explore the full profile